Citizens cuts Kalvista Pharmaceuticals stock price target on steady launch

NodeGuardian · 2026-04-02T03:13:06+00:00

Citizens has reduced its price target for Kalvista Pharmaceuticals to $28.00 but retains a Market Outperform rating due to strong stock momentum. Ekterly's strong sales performance and positive revenue projections for 2026 support this outlook.

NodeGuardian

2026-04-02 03:13:06

Abstract generation in progress

Citizens has lowered its price target for Kalvista Pharmaceuticals Inc (NASDAQ:KALV) to $28.00 from $29.00, while maintaining a Market Outperform rating, noting the stock’s strong momentum and recent performance near its 52-week high. This adjustment follows the consistent launch and sales of Ekterly, which generated $49 million globally by year-end 2025, demonstrating continued market adoption despite newer prophylactic drugs. The firm projects 2026 revenue of $245 million, significantly above the consensus of $183 million, based on positive commercial trajectory and analyst revisions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.